Cogent Biosciences, Inc.
COGT
$34.12
-$0.26-0.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.93M | 14.37M | 13.38M | 11.90M | 11.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.49M | 83.36M | 75.58M | 74.93M | 73.73M |
| Operating Income | -99.49M | -83.36M | -75.58M | -74.93M | -73.73M |
| Income Before Tax | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.49M | -80.93M | -73.53M | -71.99M | -67.93M |
| EBIT | -99.49M | -83.36M | -75.58M | -74.93M | -73.73M |
| EBITDA | -98.87M | -82.71M | -74.93M | -74.29M | -73.11M |
| EPS Basic | -0.68 | -0.59 | -0.64 | -0.63 | -0.61 |
| Normalized Basic EPS | -0.39 | -0.37 | -0.40 | -0.40 | -0.35 |
| EPS Diluted | -0.68 | -0.59 | -0.64 | -0.63 | -0.61 |
| Normalized Diluted EPS | -0.39 | -0.37 | -0.40 | -0.40 | -0.35 |
| Average Basic Shares Outstanding | 150.08M | 137.62M | 114.54M | 113.38M | 111.20M |
| Average Diluted Shares Outstanding | 150.08M | 137.62M | 114.54M | 113.38M | 111.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |